about
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial.Understanding Real Life Treatment Patterns Among Patients With Hypertension: A Markov Model.Comparative study of complete versus incomplete Kawasaki disease in 59 pediatric patients.Neuropsychological Impairment in Detoxified Alcohol-Dependent Subjects with Preserved Psychosocial FunctioningVitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism.Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma.Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab TrialsPCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumabAlirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trialsEfficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trialAlirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studiesAssociations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus controlTreatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studiesEffects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
P50
Q33730396-6D69C12F-B3F9-4E3D-AA13-05E46B4E1A48Q38452484-61289061-6A40-4EA8-8A9C-AA6A1BC7A7E0Q39750226-24038385-E9C7-4307-B2B9-6BFC52370D41Q40377648-E87DB015-77BE-472F-8A68-D19C25626B39Q42369809-F3ED9A02-9C04-440C-846E-DC4D68BC0E62Q44953633-05800149-D487-45A2-BCF1-8051151FB45CQ46919747-15131D71-C434-486A-AF32-C2B001415BCBQ48196926-4F26A92C-8342-4202-87F0-2BF373360E28Q48254766-07E99A20-9FFF-4EA8-AA64-74591474155CQ50047295-9D0B0CB5-97B6-4DFF-9220-3955D88AD2C8Q51746011-9F3AB0D3-3965-42DB-9F3C-B394D40BD3FBQ52662066-FA7B9FD8-2CBE-4D41-A30C-44E8AC340280Q58127079-DAF70B43-F5A1-4392-8FF8-780188C89B6AQ64109215-0C91296B-B697-4680-96A6-3CA3E5E1FEF1Q64894407-99217D71-59B2-4BB6-85DF-0C2AD93E643CQ88869032-E9DC8943-CB82-4AB3-97D3-1D2EE63A2717Q90613974-F1226FA4-6425-439D-BB2E-B9DF6D9FF1ACQ91207655-A729D3B8-25C4-4A48-93EB-9F433B85DBDFQ92205704-99E7B264-7D06-40AB-B648-FBB3CCE5FBD3Q92385369-495B17BA-931C-48BD-B44B-D8F8C0F7EEA1Q92990025-1B9C0129-689E-4574-984E-8CD450DBA8BA
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Alexia Letierce
@en
Alexia Letierce
@nl
type
label
Alexia Letierce
@en
Alexia Letierce
@nl
prefLabel
Alexia Letierce
@en
Alexia Letierce
@nl
P108
P31
P496
0000-0001-6679-5772